Liftstream Ltd

Liftstream provides executive search services and interim management resource to businesses operating in the area of life sciences. The life sciences market demands the very highest professional capability and acumen in the people it employs, from scientific functions oriented towards research, discovery and development of transformational bioscience and medical technologies, through to their commercialisation. Liftstream’s executive search recruitment practice brings together unparalleled levels of market research, people engagement and deep client understanding to recruit and employ the right people for the life science clients we represent. Executive Search in Life Sciences Interim management is a growing feature of the life sciences sector as it offers access to the very specific skills and experience demanded by particular projects or company strategies. Liftstream offers highly selected interim management professionals from the management and executive levels of life sciences, across most central functions. Interim Management in Life Sciences Bringing compatible people together in an environment and culture from which they can mutually benefit and develop remains the primary function of Liftstream. At Liftstream we believe individuality makes our role all that more vital and so we've engendered a culture where relationships are of primary importance and people's unique career or recruitment requirements are the centre of our focus across the respective areas of life sciences. Pharmaceutical Executive Search Biotechnology Executive Search Medical Device Executive Search Medical Diagnostic Executive Search
Company Type
Company Sub-Type
Twitter Account
@liftstream

LucyJRobertshaw

Lucy J Robertshaw specialize in the Anglo Nordic Life Sciences sectors. Our expertise includes match making for export opportunities and talent spotting for investment. We are immersed in the market and highly visible at important industry events. We have many years experience within the Pharmaceutical sector bringing a wealth of knowledge and expertise to our clients who are looking to develop their business. We have personal and professional relationships with key players and an ear to the ground in Scandinavia and the UK. We understand the challenges within the life science sector and bring a new outlook to business development. We are offering clients support, from an idea they may have, to understanding how to create a business model and right through to ensure they are marketed correctly with the right strategy.
Company Type
Company Sub-Type
Twitter Account
@lucyrobershaw2

Masters Speciality Pharma

    Founded over 30 years ago, Masters Speciality Pharma is an international pharmaceutical company specialising in the distribution of unlicensed medicinal products to Physicians, Hospitals, Clinics, Government institutions and individual patients, providing access to essential life-saving treatments worldwide.

Masters is fully compliant with regulatory requirements in all jurisdictions enabling us to deliver tailored medical solutions to over 90 countries worldwide, and is trusted as a reliable source of pharmaceutical product
Company Type
Company Sub-Type

Medherant Limited

Medherant is a leading developer of next-generation transdermal drug delivery patches.

Transdermal delivery of drugs from a patch provides better control of the dose than achieved with gels, ointments and creams.  However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch.  Medherant’s TEPI Patch® is formulated with a novel polymer adhesive that is mixed with the drug.

One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch.  The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove.

Medherant is developing its own TEPI Patch® products and working with third parties to assess the suitability of the technology for their drugs.  

The Company expects to earn revenues from licensing both its products and its technology for use with specific drugs.

Company Type
Company Sub-Type
Twitter Account
@medherant

MediWales

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Company Type
Company Sub-Type
Twitter Account
@mediwales

MGB Biopharma Ltd

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.

Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections. MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Company Type
Company Sub-Type
Twitter Account
@MGB_Biopharma

Mironid

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Company Type
Twitter Account
@mironidltd

OFX

OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model. 
Company Type

Oxford Genetics

Oxford Genetics is a specialist synthetic biology company based in Oxford, United Kingdom, and our goal is to accelerate the discovery, development and production of proteins, antibodies, viruses and bio-therapeutics (biologics, gene/cell therapies) through the application of synthetic biology.  We are focused on providing DNA, protein, virus and cell line solutions for mammalian expression and bio-production.  From DNA design/synthesis, through antibody development, and using vectors to produce proteins/antibodies/viruses on the backend, Oxford Genetics delivers. Our team pride themselves on understanding the biological purpose of our customer’s projects, and work hand-in-hand to design, construct and validate the systems needed, providing a complete synthetic biology solution from design to delivery.  

Company Type
Company Sub-Type
Twitter Account
@OxfordGenetics

Oxstem

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology.

The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.

Company Type
Twitter Account
@OxStem